Advertisement

Cannabidiol (CBD) Consideration in Parkinson Disease

      Highlights

      • Parkinson disease (PD) leads to many noticeable motor and nonmotor symptoms.
      • Pharmacologic treatments for PD symptoms have been found to be especially helpful when combined with nonpharmacologic approaches.
      • Cannabidiol has been used for PD symptom management.
      • However, more human model randomized clinical trials are needed for cannabidiol use in PD.

      Abstract

      Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by the decrease in dopaminergic neurons in the brain leading to motor and nonmotor symptoms. With the increased availability of cannabidiol in the United States and interest in the PD community for PD-related symptom management in complementary to pharmacologic treatment, this review provides nurse practitioners with useful information on existing studies and regulatory considerations on the implication of cannabidiol in PD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jankovic J.
        Parkinson’s disease: clinical features and diagnosis.
        J Neurol Neurosurg Psychiatry. 2008; 79: 368-376
        • Parkinson’s Foundation
        Non-Movement Symptoms.
        • National Institute for Health and Care Excellence (NICE)
        Parkinson’s disease in adults: diagnosis and management. NICE guideline NG71.
        July 2017
        • Gomperts S.N.
        Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia.
        Continuum. 2016; 22: 435-463https://doi.org/10.1212/CON.0000000000000309
        • Parkinson’s Foundation
        What is Parkinson’s? Causes.
        • Crippa J.A.S.
        • Hallak J.E.C.
        • Zuardi A.W.
        • Guimarães F.S.
        • Tumas V.
        • Dos Santos R.G.
        Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?.
        Eur Arch Psychiatry Clin Neurosci. 2019; 269: 121-133https://doi.org/10.1007/s00406-019-00982-6
        • Wei Y.J.
        • Palumbo F.B.
        • Simoni-Wastila L.
        • et al.
        Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a Medicare Part D population.
        Value Health. 2014; 17: 196-204https://doi.org/10.1016/j.jva1.2013.12.003
        • Gerlach O.H.H.
        • Winogrodzka A.
        • Weber W.E.J.
        Clinical problems in the hospitalized Parkinson’s disease patient: systematic review.
        Mov Disord. 2011; 26: 197-208
        • Seppi K.
        • Ray Chaudhuri K.
        • Coelho M.
        • et al.
        Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review.
        Mov Disord. 2019; 34: 180-198https://doi.org/10.1002/mds.27602
        • Witt K.
        • Kalbe E.
        • Erasmi R.
        • Ebersbach G.
        Nichtmedikamentöse Therapieverfahren beim Morbus Parkinson [Nonpharmacological treatment procedures for Parkinson’s disease].
        Nervenarzt. 2017; 88: 383-390https://doi.org/10.1007/s00115-017-0298-y
        • Armstrong M.J.
        • Okun M.S.
        Diagnosis and treatment of Parkinson disease: a review.
        JAMA. 2020; 323: 548-560https://doi.org/10.1001/jama.2019.22360
        • Vickery A.
        • Finch P.
        Cannabis: are there any benefits?.
        Intern Med J. 2020; 50: 1326-1332https://doi.org/10.1111/imj.15052
        • VanDolah H.
        • Bauer B.
        • Mauck K.
        Clinicians’ guide to cannabidiol and hemp oils.
        Mayo Clin Proc. 2019; 94: 1840-1851https://doi.org/10.1016/j.mayocp.2019.01.003
        • Brenan M.
        14% of Americans Say They Use CBD Products.
        Gallup. August 7, 2019;
        • Ferreira-Junior N.C.
        • Campos A.C.
        • Guimarães F.S.
        • et al.
        Biological bases for a possible effect of cannabidiol in Parkinson’s disease.
        Braz J Psychiatry. 2020; 42: 218-224https://doi.org/10.1590/1516-4446-2019-0460
        • Chagas M.H.
        • Zuardi A.W.
        • Tumas V.
        • et al.
        Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial.
        J Psychopharmacol. 2014; 28: 1088-1098https://doi.org/10.1177/0269881114550355
        • Leehey M.A.
        • Liu Y.
        • Hart F.
        • et al.
        Safety and tolerability of cannabidiol in Parkinson disease: an open label, dose-escalation study.
        Cannabis Cannabinoid Res. 2020; 5: 326-336https://doi.org/10.1089/can.2019.0068
        • Thanabalasingam S.J.
        • Ranjith B.
        • Jackson R.
        • Wijeratne D.T.
        Cannabis and its derivatives for the use of motor symptoms in Parkinson’s disease: a systematic review and meta-analysis.
        Ther Adv Neurol Disord. 2021; 1417562864211018561https://doi.org/10.1177/17562864211018561
        • Greenwich Biosciences
        Epidiolex (cannabidiol).
        • Giuliano C.
        • Francavilla M.
        • Ongari G.
        • et al.
        Neuroprotective and symptomatic effects of cannabidiol in an animal model of Parkinson’s disease.
        Int J Mol Sci. 2021; 22: 8920https://doi.org/10.3390/ijms22168920
        • Parkinson’s Foundation
        Parkinson’s Foundation Consensus Statement on the Use of Medical Cannabis for Parkinson’s Disease.
        (Published 2020)
        • Hawes E.
        • Lee C.
        • Brackney D.
        • Ensley T.
        • Kidd J.
        • Page C.
        Cannabidiol products: review of the regulatory and clinical considerations.
        J Nurse Pract. 2020; 16: 747-755https://doi.org/10.1016/j.nurpra.2020.07.022
        • Casarejos M.J.
        • Perucho J.
        • Gomez A.
        • et al.
        Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy.
        J Alzheimers Dis. 2013; 35: 525-539
        • Lotan I.
        • Treves T.A.
        • Roditi Y.
        • et al.
        Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.
        Clin Neuropharmacol. 2014; 37: 41-44
        • Drugs.com
        Drug interaction report.
        • Bauer B.A.
        What are the benefits of CBD—and is it safe to use?.
        (Published December 18, 2020)

      Biography

      Helen Kim, BSN, RN, University of Washington Medical Center, Seattle.

      Biography

      Sharon Zhang, BSN, RN, Seattle University College of Nursing, Seattle, WA.

      Biography

      Mo-Kyung Sin, PhD, RN, is an associate professor at Seattle University College of Nursing, Seattle, WA, and can be contacted at [email protected]